Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.65 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12179846 | 0.86 | GABRA1 (0.61) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL4008105 | 0.86 | GABRA1 (0.61) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL2197723 | 0.86 | GABRA1 (0.61) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL13211036 | 0.83 | GABRA1 (0.69) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL2197561 | 0.83 | GABRA1 (0.59) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL2198326 | 0.79 | GABRA1 (0.55) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL3014289 | 0.77 | LMNA (0.45) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL8290784 | 0.77 | LMNA (0.53) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL6627698 | 0.76 | GABRA1 (0.65) | GABRA1PFKFB3MMP8MMP3PFKFB4 | |
| SCHEMBL14168304 | 0.75 | GABRA1 (0.39) | GABRA1PFKFB3MMP8MMP3PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0894088-A4 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1077968-A1 | NAPHTHO[2,3-B]HETEROAR-4-YL DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6121271-A | ANTIDIABETIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| US-6034093-A | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1999058522-A1 | NAPHTHO[2,3-B]HETEROAR-4-YL DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999021869-A1 | ERYTHROMYCIN A, 11,12-CARBAMATE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1999-05-06 | — | — | WO | disclosed |
| EP-0894088-A1 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998024784-A1 | SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | GABRA1 3476/4885PFKFB3 952/4885MMP8 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.